Hypoglycemia – Pipeline Review, H1 2019

Global Markets Direct’s, ‘Hypoglycemia – Pipeline Review, H1 2019’, provides an overview of the Hypoglycemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypoglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Hypoglycemia

– The report reviews pipeline therapeutics for Hypoglycemia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hypoglycemia therapeutics and enlists all their major and minor projects

– The report assesses Hypoglycemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hypoglycemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hypoglycemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hypoglycemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adocia SAS

AMAG Pharmaceuticals Inc

Arecor Ltd

Eiger BioPharmaceuticals Inc

Eli Lilly and Co

LATITUDE Pharmaceuticals Inc

Novartis AG

Rezolute Inc

Sosei Heptares

Therakind Ltd

USV Pvt Ltd

XERIS Pharmaceuticals Inc

Zealand Pharma AS

Zucara Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypoglycemia Overview

Hypoglycemia Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hypoglycemia Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypoglycemia Companies Involved in Therapeutics Development

Adocia SAS

AMAG Pharmaceuticals Inc

Arecor Ltd

Eiger BioPharmaceuticals Inc

Eli Lilly and Co

LATITUDE Pharmaceuticals Inc

Novartis AG

Rezolute Inc

Sosei Heptares

Therakind Ltd

USV Pvt Ltd

XERIS Pharmaceuticals Inc

Zealand Pharma AS

Zucara Therapeutics Inc

Hypoglycemia Drug Profiles

avexitide acetate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasiglucagon Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Hypoglycemia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3143753 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3185643 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-900018 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RZ-358 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize GLP-1 Receptor for Congenital Hyperinsulinism and Hypoglycemia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZT-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypoglycemia Dormant Projects

Hypoglycemia Discontinued Products

Hypoglycemia Product Development Milestones

Featured News & Press Releases

Mar 25, 2019: Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019

Mar 25, 2019: Xeris Pharmaceuticals presents new clinical and economic impact data on its developmental ready-to-use Glucagon

Mar 14, 2019: Xeris Pharmaceuticals doses first patient in phase 2 trial evaluating its ready-to-use glucagon to address exercise-induced hypoglycemia

Mar 07, 2019: Zealand Pharma begins dosing in Phase III trial for CHI

Feb 13, 2019: XOMA receives $5.5 Million payment from Rezolute

Feb 12, 2019: Adocia to present new clinical data on BioChaperone Glucagon at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)

Feb 04, 2019: Eiger BioPharmaceuticals announces oral presentation of phase 2 PREVENT study of avexitide in post-bariatric hypoglycemia (PBH) at upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans

Jan 17, 2019: LATITUDE Pharmaceuticals receives notice of allowance for U.S. Patent Covering Stabilized Aqueous Glucagon Formulations

Dec 20, 2018: European medicines agency grants orphan drug designation for Xeris’ investigational ready to use glucagon for the treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS)

Dec 11, 2018: Eiger BioPharmaceuticals provides update on Avexitide at 2018 R&D Day

Nov 12, 2018: Xeris Pharmaceuticals releases additional phase 3 clinical trial data on its ready-to-use Liquid Glucagon Pen

Oct 23, 2018: Xeris Pharmaceuticals announces FDA acceptance for review of NDA for its ready-to-use Glucagon Rescue Pen

Oct 16, 2018: Eiger BioPharmaceuticals announces positive results in phase 2 PREVENT study of Avexitide targeting GLP-1 in post-bariatric hypoglycemia (PBH)

Sep 27, 2018: Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children

Sep 18, 2018: Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hypoglycemia, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Hypoglycemia Pipeline by Adocia SAS, H1 2019

Hypoglycemia Pipeline by AMAG Pharmaceuticals Inc, H1 2019

Hypoglycemia Pipeline by Arecor Ltd, H1 2019

Hypoglycemia Pipeline by Eiger BioPharmaceuticals Inc, H1 2019

Hypoglycemia Pipeline by Eli Lilly and Co, H1 2019

Hypoglycemia Pipeline by LATITUDE Pharmaceuticals Inc, H1 2019

Hypoglycemia Pipeline by Novartis AG, H1 2019

Hypoglycemia Pipeline by Rezolute Inc, H1 2019

Hypoglycemia Pipeline by Sosei Heptares, H1 2019

Hypoglycemia Pipeline by Therakind Ltd, H1 2019

Hypoglycemia Pipeline by USV Pvt Ltd, H1 2019

Hypoglycemia Pipeline by XERIS Pharmaceuticals Inc, H1 2019

Hypoglycemia Pipeline by Zealand Pharma AS, H1 2019

Hypoglycemia Pipeline by Zucara Therapeutics Inc, H1 2019

Hypoglycemia Dormant Projects, H1 2019

Hypoglycemia Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Hypoglycemia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports